Positive Outlook for TuHURA Biosciences: Strategic Initiatives and Upcoming Catalysts Support Buy Rating

TuHURA Biosciences (HURA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Robert Burns from H.C. Wainwright reiterated a Buy rating on the stock and has a $12.00 price target.

Robert Burns has given his Buy rating due to a combination of factors, including TuHURA Biosciences’ strategic initiatives and financial projections. The company reported a net loss for 1Q25 that was close to expectations, and although expenses were slightly higher than anticipated, the firm maintains a solid cash position. Burns anticipates a significant equity raise in the near term, which is expected to bolster the company’s financial standing.
Additionally, several upcoming catalysts contribute to the positive outlook. These include the completion of a merger with Kineta, which will provide TuHURA with access to a promising VISTA-targeted monoclonal antibody. The initiation of multiple clinical trials in 2025, including a Phase 3 trial for IFx-2.0 and a Phase 2 trial for a VISTA-targeted antibody, are expected to drive future growth. The valuation, based on a discounted cash flow model, supports a price target of $12 per share, factoring in probabilities of approval for key pipeline products. Despite inherent risks, such as potential negative clinical outcomes and competitive pressures, the overall assessment suggests a favorable investment opportunity.

In another report released on May 5, Maxim Group also maintained a Buy rating on the stock with a $15.00 price target.